J&J’s Stelara Deemed Unaffordable For Colorado Residents By PDAB

By Luke Zarzecki, Gabrielle Wanneh / June 7, 2024 at 7:11 PM
Colorado’s prescription drug affordability board (PDAB) unanimously voted Friday (June 7) that Janssen Biotech’s Stelara, approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, is unaffordable for the state’s residents despite protests from the company. Although the board hasn’t yet decided whether to set an upper payment limit mandating lower pricing, the decision raised concerns from some members of the public that it could lead to Stelara no longer being sold in Colorado. Johnson &...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.